Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients